Purchase this article with an account.
Han Yue, Jiang Qian, Jie Guo, Yifei Yuan, Rui Zhang, Qin Ge; Pharmaceutical Treatment of Orbital Vascular Malformation: Intralesional Injection of Pingyangmycin. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1256.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficiency and safety of intralesional injection of Pingyangmycin for the treatment of orbital vascular malformations.
This study reported 13 patients received intralesional injection of Pingyangmycin at Eye and ENT Hospital of Fudan University in China. CT scan with graphic processing software was applied to calculate the volumes of lesions before and after the injection to demonstrate the change of volumes quantificationally.
In the 13 patients, there were 5 (38.5%) male and 8 (61.5%) female, with the average age of 36.1 years (range, 16-58 years). Six (46.2%) patients were dignosised as venous malformation, six (46.2%) as cavernous hemangioma and one (7.7%) as lymphangioma. Proptosis and eyelid swelling were the most common presenting signs. The mean injection dose of Pingyangmycin was 4.2 mg (range, 2-6 mg). The preoperative volume of lesions was 4.4 cm3 on average (range, 1.6-8.8 cm3), and reduced to 1.5 cm3 (range, 0.2-6.6 cm3) after Pingyangmycin treatment at a time interval of 6.6 months on average (range, 1.6-21.4 months); and the mean percentage of the volume reduction was 68.8% (range, 24.5-88.3%). Statistically, the volumes of lesion diminished significantly (Matched t-Test, t=6.7, P<0.001). And no one showed local or systemic side effects during follow-ups (mean, 11.5 months; range, 2.3-23.4 months).
Intralesional injection of Pingyangmycin for the treatment of orbital vascular malformation is safe and effective.
This PDF is available to Subscribers Only